Clinical TrialID 6822

Cantharidin Application in Molluscum Patients-1

NCT03377790

Molluscum Contagiosum

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id
6822
Evidence Id
6822
Core Evidence Id
6822
Source Clinical Trial Id
6812
Herb2 Clinical Trial Id
HBCT006812
Nct Id
NCT03377790
Title
Cantharidin Application in Molluscum Patients-1
Status
Completed
Phase
Phase 3
Study Result
Yes
Study Condition
Molluscum Contagiosum
Study Type
Interventional
Study Design
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
Intervention
COMBINATION_PRODUCT: VP-102 - Cantharidin, Topical Film Forming Solution|COMBINATION_PRODUCT: Placebo -Topical Film Forming Solution without VP-102
Intervention Allocation
Randomized
Intervention Model
Parallel
Intervention Mask
Quadruple
Intervention Purpose
Treatment
Gender
All
Age
Child, Adult, Older_Adult
Enrollment
266
Outcome Measure
Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS), Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 84 visit (EOS)., Day 1 (Baseline and new) compared to Day 84 (EOS)
Sponsor Collaborator
Verrica Pharmaceuticals Inc.|Instat Consulting, Inc.|Paidion Research, Inc.|Database Integrations, Inc.
Funded By
INDUSTRY
Location
Alabama Clinical Therapeutics, Birmingham, Alabama, 35205, United States|Southeastern Pediatric Associates, Dothan, Alabama, 36305, United States|Applied Research Center of Arkansas, Little Rock, Arkansas, 72212, United States|Study Protocol, Inc.,, Boynton Beach, Florida, 33437, United States|Skin Research Institute, Coral Gables, Florida, 33146, United States|ASCLEPES Research Center, Spring Hill, Florida, 34609, United States|Olympian Clinical Research, Tampa, Florida, 33609, United States|Summit Dermatology, Oakbrook Terrace, Illinois, 60181, United States|Clarkston Skin Research, Clarkston, Michigan, 48346, United States|St Louis Children's Hospital, Saint Louis, Missouri, 63104, United States|Midwest Children's Hospital, Lincoln, Nebraska, 68522, United States|Kings County Hospital, Brooklyn, New York, 11203, United States|University North Carolina Dermatology Center, Chapel Hill, North Carolina, 27516, United States|The Pediatric Associates of Fairfield, Inc, Fairfield, Ohio, 45014, United States|Holston Medical Group, Bristol, Tennessee, 37620, United States|Arlington Research Center, Arlington, Texas, 66011, United States|Center for Skin Research, Houston, Texas, 77056, United States|ACRC Trials Plano Pediatrics, Plano, Texas, 75093, United States
Other Id
VP-102-101
Start Date
2018-03-21
Primary Completion Date
2018-11-26
Completion Date
2018-11-26
First Posted
2017-12-19
Results First Posted
2021-12-14
Last Update Posted
2022-01-11
Study Document
Study Protocol, https://cdn.clinicaltrials.gov/large-docs/90/NCT03377790/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/90/NCT03377790/SAP_001.pdf
Study Url
https://clinicaltrials.gov/study/NCT03377790
Title Cn
Title En
Cantharidin Application in Molluscum Patients-1
Bilingual Status
semi_complete